FDA grants orphan drug status to CAR-T for T-cell acute lymphoblastic leukemia

The FDA granted orphan drug designation to WU-CART-007 for patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
WU-CART-007 (Wugen) is an allogeneic, gene-edited chimeric antigen receptor T-cell therapy that targets the protein CD7 on the surface of cancer cells.
The therapy, derived from healthy donor cells, uses CRISPR/Cas9 gene editing to knock out CD7 and T-cell receptor alpha constant to prevent CAR T-cell fratricide and graft-versus-host disease.
The investigational agent is the first allogeneic CAR-T for T-cell malignancies to be approved for clinical testing in the

The FDA granted orphan drug designation to WU-CART-007 for patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
WU-CART-007 (Wugen) is an allogeneic, gene-edited chimeric antigen receptor T-cell therapy that targets the protein CD7 on the surface of cancer cells.
The therapy, derived from healthy donor cells, uses CRISPR/Cas9 gene editing to knock out CD7 and T-cell receptor alpha constant to prevent CAR T-cell fratricide and graft-versus-host disease.
The investigational agent is the first allogeneic CAR-T for T-cell malignancies to be approved for clinical testing in the